iData Insights

Polycystic Kidney Disease - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 03, 2016 17:24 IST

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Polycystic Kidney Disease Overview 9

Therapeutics Development 10

Pipeline Products for Polycystic Kidney Disease - Overview 10

Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11

Polycystic Kidney Disease - Therapeutics under Development by Companies 12

Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 13

Polycystic Kidney Disease - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Polycystic Kidney Disease - Products under Development by Companies 17

Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 18

Polycystic Kidney Disease - Companies Involved in Therapeutics Development 19

DiscoveryBiomed, Inc. 19

Endocyte, Inc. 20

IC-MedTech, Inc. 21

Ipsen S.A. 22

Kadmon Corporation, LLC 23

Metabolic Solutions Development Company, LLC 24

Otsuka Holdings Co., Ltd. 25

Synta Pharmaceuticals Corp. 26

Polycystic Kidney Disease - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(ascorbic acid + menadione) - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CIM-2 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

DBM-43H11 - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Drugs for Polycystic Kidney Disease - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

EC-0371 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

GLG-302 - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

JP-153 - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

lanreotide acetate - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

MSDC-0160 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

MSDC-0602 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

oxypurinol - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

pyrimethamine - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

STA-2842 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

tesevatinib tosylate - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

tolvaptan - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Read More http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Polycystic Kidney Disease Overview 9

Therapeutics Development 10

Pipeline Products for Polycystic Kidney Disease - Overview 10

Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11

Polycystic Kidney Disease - Therapeutics under Development by Companies 12

Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 13

Polycystic Kidney Disease - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Polycystic Kidney Disease - Products under Development by Companies 17

Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 18

Polycystic Kidney Disease - Companies Involved in Therapeutics Development 19

DiscoveryBiomed, Inc. 19

Endocyte, Inc. 20

IC-MedTech, Inc. 21

Ipsen S.A. 22

Kadmon Corporation, LLC 23

Metabolic Solutions Development Company, LLC 24

Otsuka Holdings Co., Ltd. 25

Synta Pharmaceuticals Corp. 26

Polycystic Kidney Disease - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(ascorbic acid + menadione) - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CIM-2 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

DBM-43H11 - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Drugs for Polycystic Kidney Disease - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

EC-0371 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

GLG-302 - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

JP-153 - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

lanreotide acetate - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

MSDC-0160 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

MSDC-0602 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

oxypurinol - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

pyrimethamine - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

STA-2842 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

tesevatinib tosylate - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

tolvaptan - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Read More http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.